Bolstering your Alzheimer’s & Parkinson’s Pipeline to Slow, Cure & Prevent Neurodegeneration
What's New for 2025?
40+ Brand-New Speakers including fresh perspectives from Eli Lilly, Eisai, Genentech, Biogen, Novartis, AbbVie, Takeda and more
12+ New Presenting Companies including Annovis Bio, Lundbeck, Acelot, Anavex, AccureX and more
Perspectives of Patients & Clinicians on the challenges of anti-amyloid therapeutic adoption and their expectations from the next wave of neurodegenerative therapeutics
Regulatory & Commercial Discussions, expanding the end-to-end nature of the summit to include unpacking FDA’s response to αSyn SAA with C-Path, securing alignment with regulators around the optimal endpoints to demonstrate efficacy with UCB, and more
Forward Looking Insights on second-generation antibody shuttles with Roche, and novel programs including anti-taus, GLP-1s, precision genetic medicines and more
Join 150+ Your Industry Peers to:
Uncover more transformative targets, exploring beyond amyloid and tau for AD, and addressing the biological underpinnings of PD
Explore ground-breaking progress in neuro-degenerative biomarker research to strive for pre-symptomatic detection and earlier diagnosis
Discover the latest in vitro and in vivo models to understand AD and PD pathology and transform translational research
Review innovative clinical strategies to shorten trial length, mitigate presence of background therapies, and demonstrate greater efficacy
Anticipate and overcome regulatory and commercial bottlenecks in bringing a new wave of neuro-degenerative drugs to market
What Your Peers Have to Say:
